We agree with many of the comments made by Yamada et al., 1 namely that the ECG and NTproBNP are fundamental tests used in the diagnosis of heart failure and that as tests become cheaper they become more cost-effective. We further agree that our data show that hand-held echocardiography gives the greatest sensitivity, ECGs give intermediate sensitivity, and NTproBNP normal range cuts off the worst sensitivity in detecting left ventricular systolic dysfunction (LVSD). 2 We also agree that as screening sensitivity falls, some subjects with the screened-for condition will fail to have it diagnosed. Although we clearly stated that the screening programmes described would miss cases of LVSD, we did not make it clear that this was a function of screening sensitivity, an important point that we are pleased Yamada et al. have emphasized. Thus, NTproBNP-driven screening would leave more subjects with LVSD undiagnosed than ECG-or hand-held echocardiographydriven screening. However, as ECG-driven screening has much lower specificity (thus higher false positive rates) and hand-held echocardiography costs more than NTproBNP per test, our conclusion that NTproBNP or ECG screening prior to hand-held echocardiography prior to traditional echocardiography is the most cost-effective strategy, at both current test costs and future likely test costs, remains correct. Furthermore, despite its lower sensitivity, NTproBNPdriven screening might be justifiable in practice, as subjects with normal NTproBNP levels have extremely low cardiac morbidity and mortality whatever their left ventricular function, 3, 4 although long-term follow-up of our subjects would be required to confirm this. Finally, we agree that if the price of hand-held echocardiography approached that of the ECG, hand-held echocardiography would clearly become the screening method of choice. However, whether this would ever happen is unclear, and furthermore were this to happen then whether enough fully trained sonographers would be available to accurately screen for LVSD using this technology is also unclear, a major potential future issue. 
Gavin Galasko
stress that, as a corollary, MI might have a pain-free presentation characterized, instead, by sudden onset of unexplained dyspnoea and by unexplained collapse. 2 These alternative clinical stigmata of MI are well described in the elderly, 3 and might well have been a feature of many of the patients in the Rotterdam Study. The other major shortcoming of our NSF emerges in the outline of models of care to be used in hospital-wide protocols, and here the advice on the assessment of eligibility for thrombolysis deals with management of those MI patients who present with chest pain without referring to the potential benefits of thrombolysis in those who do not have chest pain. 2 Nowhere is there a recognition that a pain-free MI patient who presents to the hospital promptly with sudden onset dyspnoea or collapse might well be within the therapeutic time window for thrombolysis if the electrocardiographic criteria for such treatment are met. 
Risk assessment in acute pulmonary embolism
We read with great interest the paper by Aujesky et al.,
1 validating the prognostic model comprising 11 routinely available clinical parameters in patients with pulmonary embolism (PE). However, the presented model is of low cost but also complex. Moreover, some parameters like presence of cancer, altered mental status, severity of heart failure, and chronic lung disease, can be difficult to assess and are observerdependent. It is also remarkable that the presented model does not include increased creatinine level reflecting impaired renal function, which was reported to be an important prognostic factor in acute PE patients. 2, 3 According to the authors, this model effectively identifies patients at low risk of mortality, however, the high-risk group of fatal outcome is not unequivocally indicated. In acute PE, the medical status depends on the haemodynamic compromise mostly determined by the level of right ventricle overload. Natriuretic peptides and troponin are well-established markers of cardiovascular mortality. It is generally accepted that they reflect the severity of acute heart dysfunction in PE. 4 In 2005, there were two papers that proposed including biomarkers into risk assessment. Binder et al. 5 observed that NT-proBNP cut-off level of 1000 pg/mL had a high negative predictive value (95% for a complicated course, 100% for death), whereas troponin combined with echocardiography improved the prediction of outcome in intermediate-risk group. The second study also proved that low levels of NT-proBNP predict favourable outcome. 3 Interestingly, mortality related to PE in patients with elevated NT-proBNP and high troponin T was similar to the death rate observed in a group of patients with clinically massive embolism and reached 33%. Importantly, both biomarkers helped to stratify 40-day prognosis in acute PE for both low and high-risk groups. Therefore, on the basis of the biomarkers model, stratifying the risk in PE seems to be the option, which provides objective and accurate prognosis assessment.
